Changes in prevalence of anxiety and depression among COVID-19 patients during a two-year recovery period: A systematic review and meta-analysis

Qingxiang Shang,Ke Xu,Hong Ji,Qigang Dai,Hao Ju,Haodi Huang,Jianli Hu,Changjun Bao
DOI: https://doi.org/10.1016/j.jpsychores.2024.111602
IF: 4.62
2024-02-04
Journal of Psychosomatic Research
Abstract:Objective To analyze the temporal trend of anxiety and depression prevalences up to 2 years of follow-up for COVID-19 patients during the recovery period and to compare regional differences. Methods We performed a systematic review from PubMed, Embase, Web of Science, CNKI, Wanfang, and VIP using keywords such as "COVID-19", "anxiety", "depression", and "cohort study". Meta-analysis was performed to estimate the pooled prevalence of anxiety and depression at five follow-up time intervals. Subgroup analyses were conducted by different regions. Results 34 cohort studies were included in the meta-analyses. The pooled anxiety prevalence rates at 0–1 month, 1–3 months, 3–6 months, 6–12 months and 12–24 months were 18% (95% CI: 11% to 28%), 18% (95% CI: 12% to 28%), 22% (95% CI: 16% to 29%), 15% (95% CI: 11% to 21%), and 10% (95% CI: 0.05% to 20%), respectively, and the pooled depression prevalence rates were 22% (95%CI: 15% to 33%), 19% (95% CI: 13% to 29%), 21% (95% CI: 15% to 28%), 15% (95% CI: 11% to 20%), and 9% (95% CI: 0.4% to 21%) respectively. The prevalence of depression in Asian and non-Asian countries was statistically different at 0–1 month (χ 2 = 15.248, P < 0.001) and 1–3 months (χ 2 = 28.298, P < 0.001), and prevalence of anxiety was statistically different at 3–6 months (χ 2 = 9.986, P = 0.002) and 6–12 months (χ 2 = 7.378, P = 0.007). Conclusion The prevalence of anxiety and depression in COVID-19 patients generally tends to decrease after 2 years of recovery, but may temporarily increase at 3–6 months. There are regional differences in the changes in prevalence of anxiety and depression.
psychiatry
What problem does this paper attempt to address?